Managers / Q1 2023 · view latest →
SYQUANT CAPITAL SAS
CIK 0001766392 · 25 AVENUE KLEBER, PARIS, I0, 75116 · 0033142569307
Summary
Syquant Capital Sas reported $43M in U.S.-listed holdings across 7 positions for Q1 2023.
The portfolio is heavily concentrated: Horizon Therapeutics Pub L alone accounts for 68.7% of reported value.
Compared with Q4 2022, the fund opened 6 new positions and exited 13.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 80.0% · $35M
- Common Stock · 20.0% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| HORIZON THERAPEUTICS PUB L | NEW | +271.6K | 271.6K | +$30M | $30M |
| MONEYGRAM INTL INC | NEW | +448.2K | 448.2K | +$5M | $5M |
| AMRYT PHARMA PLC | NEW | +258.0K | 258.0K | +$4M | $4M |
| APOLLO ENDOSURGERY INC | NEW | +300.0K | 300.0K | +$3M | $3M |
| MANCHESTER UTD PLC NEW | NEW | +50.0K | 50.0K | +$1M | $1M |
| RACEFERRARI N V | NEW | +1.0K | 1.0K | +$273,000 | $273,000 |
| LHC GROUP INC | SOLD OUT | −121.1K | 0 | −$20M | $0 |
| IROBOT CORP | SOLD OUT | −113.0K | 0 | −$5M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | HORIZON THERAPEUTICS PUB L | SHS | 68.69% | $30M | 271.6K |
| 2 | MONEYGRAM INTL INC | COM NEW | 10.82% | $5M | 448.2K |
| 3 | AMRYT PHARMA PLC | SPONSORED ADS | 8.72% | $4M | 258.0K |
| 4 | APOLLO ENDOSURGERY INC | COM | 6.90% | $3M | 300.0K |
| 5 | FTITECHNIPFMC PLChistory → | COM | 1.68% | $723,000 | 53.0K |
| 6 | RACEFERRARI N V | COM | 0.63% | $273,000 | 1.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $447M | 38 | Jul 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $640M | 40 | Apr 10, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $817M | 37 | Jan 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $348M | 17 | Oct 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $302M | 14 | Jul 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2025 | $141M | 14 | Apr 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $70M | 6 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $27M | 5 | Oct 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $10M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $64M | 6 | Apr 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $22M | 7 | Jan 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $255M | 9 | Oct 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $138M | 11 | Jul 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $43M | 7 | Apr 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $41M | 14 | Jan 17, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $165M | 25 | Oct 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $90M | 32 | Jul 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $195M | 35 | Apr 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $262M | 43 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $164M | 42 | Oct 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $83M | 41 | Jul 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $386M | 53 | Apr 20, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $387M | 81 | Feb 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $196M | 62 | Oct 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $215M | 23 | Aug 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $407M | 18 | Apr 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $194M | 16 | Jan 8, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $365M | 17 | Oct 17, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $312M | 14 | Jul 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $258M | 15 | Apr 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $117M | 11 | Feb 4, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.